Skip to main content
← Back to companies
X4 Pharmaceuticals logo

X4 Pharmaceuticals

0 open
Cambridge, Massachusetts, United StatesFounded 2014111+ employees$760.6M raisedIPOXFOR
Last round: post ipo equity · $155.3M · Oct 2025(13 rounds total)
5 layoff events · Last: Nov 2025
Founded by Henri Termeer, Keith Flaherty, Paula Ragan, Renato Skerlj, Richard Peters
Backed by(23 investors)
New Enterprise AssociatesCoastlands CapitalHercules CapitalAcorn BioventuresCormorant Asset ManagementLumira VenturesNantahala Capital ManagementBiotechnology Value FundKalehua CapitalDeep Track CapitalStonepine Capital ManagementTrails Edge Capital PartnersBain Capital Life SciencesAbingworthSV Health Investors

We are a fully integrated, commercial-stage biopharmaceutical company driving progress for people living with rare immune disorders. We listen to people whose challenges have been long overlooked, understand their needs, and develop solutions to their most urgent and critical health concerns. Our FDA-approved medication XOLREMDI® (mavorixafor) is commercially available in the U.S. in its first indication. We are evaluating mavorixafor in additional potential indications, and have an ongoing global, pivotal Phase 3 clinical trial for its use in chronic neutropenia. Our corporate headquarters is in Boston, Massachusetts.

Open Positions at X4 Pharmaceuticals (0 Jobs)

No open positions at the moment.

Browse All Jobs

Ready to start your space career at X4 Pharmaceuticals?

Shipping like we're funded. We're not. No affiliation.

Sequoia logo
Y Combinator logo
Founders Fund logo
a16z logo